Immunotherapy after surgery — why it's given even when the tumour is already gone

Adjuvant immunotherapy is checkpoint inhibitor immunotherapy given after surgery has already removed all visible tumour — not because cancer is still seen on a scan, but because the removed tissue's pathology report shows a meaningful risk that microscopic cancer cells were left behind, too small for any scan to detect. It is intended to lower that recurrence risk in a proportion of eligible patients, over a defined course of treatment.

Most patients who ask about this are not actually eligible for it. It is offered to a specific subset of patients whose pathology report shows higher-risk features — it is not a routine add-on offered after every cancer surgery, and it is not offered "just in case". If your surgeon or oncologist has not raised it, that is usually because your own pathology findings did not meet the threshold, not because it was overlooked.

This page sets out the recurrence-risk logic behind why it's given, who it's actually offered to, and for how long — including the real option of not having it, which applies to more patients than most sources admit.

Most patients who have had cancer surgery do not have this combination of features and are not offered adjuvant immunotherapy at all — that is the common, expected outcome for most people, not a gap in their care.

Approved adjuvant checkpoint inhibitor regimens are given for a defined, fixed course — commonly cited in NCCN and ASCO patient-education guidance as up to around one year, depending on the specific cancer and approved regimen. It is administered as day care infusion cycles at intervals of a few weeks each, not as a daily tablet and not continued indefinitely.

Your oncologist sets the exact number of cycles and reviews the plan at intervals — including stopping early if side effects become significant, or if surveillance scans (coordinated with partner imaging centres) raise a new concern. The schedule is fixed at the start, but it is not rigid once treatment is underway.

"Gone from the scan" is not the same as "gone from the body." Surgery removes what can be seen and felt, but some cancers shed microscopic cells into the bloodstream or nearby tissue before the operation ever happens — far too few and far too small for a CT, PET-CT, or MRI to pick up. These leftover cells are what recurrence usually comes from later, sometimes months or years after a surgery that appeared completely successful at the time.

Checkpoint inhibitor immunotherapy does not shrink a tumour in this setting — there is none left to shrink. Instead, it works by releasing a brake on the immune system's own T-cells, aiming to help the body recognise and clear these leftover microscopic cells during the window when the overall disease burden is at its lowest. That is also why timing matters: adjuvant treatment is generally started within a defined window after surgical recovery, not months later once the opportunity has passed.

Yes. Even for the subset of patients who are eligible, declining adjuvant immunotherapy in favour of structured active surveillance — regular scans and check-ups designed to catch any recurrence early — is a real, respected medical option, not a failure to "do everything possible." Many patients weigh a year of infusion cycles, potential side effects, and travel to a treatment centre against a recurrence risk that, for their specific pathology, is meaningful but not overwhelming, and decide surveillance is the right fit for their own priorities.

There is no universally "correct" answer here — the right choice depends on how your own pathology risk features weigh against what a year of treatment would mean for your life, which is a conversation to have honestly with your oncologist, not a decision to make from a table of general risk factors alone.

• Is Immunotherapy Painful? What the Treatment Actually Involves — a realistic picture of the infusion cycles themselves, for anyone weighing whether a year of treatment is worth it.
• Immunotherapy vs Targeted Therapy: They Are Not the Same — useful if your oncologist has mentioned either as an adjuvant option and the difference isn't clear.
• Understanding Your Treatment Plan: Cycles, Weeks and Duration — how the fixed adjuvant course described above actually plays out on a calendar.
• Immunotherapy at CION Cancer Clinics — the full picture of how CION supports patients through this decision, from pathology review to treatment.

This page is for general information and does not replace a consultation. Recurrence-risk features and treatment durations described here are general and drawn from NCCN/ASCO patient-education guidance — they are not a prediction of outcome for any individual patient, and do not represent a survival statistic of any kind.

Thousands have asked exactly this after surgery

Wanting to understand why treatment is being recommended after the tumour is already out is not distrust — it's how informed patients make this decision. Our team walks through your specific pathology report, honestly.